ClinicalTrials.gg
CompletedNCT01136174Updated Jan 6, 2015Results posted

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

A Phase 2 interventional study of Placebo and BIBF 1120 in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 8 sites in Japan. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-01-06.

Sponsored by Boehringer Ingelheim · Phase 2 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
8th of 16
50 · median 49
Started
2010
the only one that year
Phase 2
3 of 16
1 open now
Registered
1st of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 8th largest by enrollment, is the only one that started in 2010, is one of 3 in phase 2, and was the 1st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

To investigate safety of BIBF 1120 in Japanese patients with idiopathic pulmonary fibrosis (IPF), with and without pirfenidone background treatment.

To assess pharmacokinetics of BIBF 1120 in Japanese patients, with and without pirfenidone background treatment.

To assess pharmacokinetics of pirfenidone in Japanese patients, alone and in combination with BIBF 1120 treatment.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of idiopathic pulmonary fibrosis (IPF) according to American Thoracic Society (ATS) /European Respiratory Society (ERS) guideline
  2. Forced vital capacity (FVC) 50-90%
  3. Diffusing capacity for carbon monoxide (DLCO) 30-79%
  4. For patients on pirfenidone, have been on a steady dose for at least 3 months

Exclusion criteria

Exclusion criteria:

  1. (AST), alanine aminotransferase (ALT) > 1.5 x (ULN) at screening.
  2. > 1.5 x ULN at screening.
  3. Relevant airways obstruction (i.e. pre-bronchodilator /FVC \<0.7) at screening.
  4. Continuous oxygen supplementation.
  5. Active infection at screening or randomisation.
  6. Being treated with any of the following concomitant medications.

    • Oral medication at unstable dose
    • ketoconazole or atazanavir
  7. Patients who are expected to go on to lung transplantation, have rapidly deteriorating disease, or have a less than 3 months from screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
50 participants (actual)

Study arms

  • Experimental
    BIBF 1120 50 mg

    Low dose for cohort 1

    Drug: BIBF 1120

  • Experimental
    BIBF 1120 100 mg

    Middle dose for cohort 2

    Drug: BIBF 1120

  • Experimental
    BIBF 1120 150 mg

    High dose for cohort 3

    Drug: BIBF 1120

  • Placebo comparator
    Placebo

    Placebo for cohort 1,2,3

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo BID for cohort 1,2,3

  • 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

  • 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

  • 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively

06

What researchers measure

Primary outcomes

  1. Drug-related Adverse Events

    The number of patients with drug-related adverse events stratified according to pirfenidone use in each group

    Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days

Secondary outcomes

  1. AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

    AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

    Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

  2. Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

    Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

  3. AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone

    AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

    Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

  4. Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

    Time frame: pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)

  5. AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

    AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.

    Time frame: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

  6. Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)

    Time frame: Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

  7. AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

    AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.

    Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

  8. Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)

    Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose

  9. AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

    AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.

    Time frame: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

  10. Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)

    Time frame: Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

  11. AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

    AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.

    Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

  12. Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

    Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)

    Time frame: Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose

  13. Withdrawal Due to Adverse Event

    Number of patients prematurely discontinued from trial medication due to adverse event.

    Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days

  14. Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background

    Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background

    Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days

  15. Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background

    Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background

    Time frame: after the first drug intake until 28 days from the last treatment administration, up to 60 days

  16. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  17. Change From Baseline in Pulse Rate

    Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  18. Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)

    Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  19. Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)

    Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  20. Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)

    Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  21. Lung Function Measurement: Forced Vital Capacity (FVC)

    Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

  22. Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)

    Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

    Time frame: baseline and day 35

07

Results

Posted Jan 6, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Started126824
Completed126820
Not completed0004
Withdrew: Adverse event0004

Outcome measures

PrimaryDrug-related Adverse Events

The number of patients with drug-related adverse events stratified according to pirfenidone use in each group

Time frame:
after the first drug intake until 28 days from the last treatment administration, up to 60 days
Reported as:
Number · participants
Drug-related Adverse Events
participantsPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Patients with Pirfenidone (N = 5, 4, 4, 13)1007
Patients without Pirfenidone (N = 7, 2, 4, 11)1013
SecondaryAUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

Time frame:
pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Reported as:
Geometric mean · ng*h/mL
AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
ng*h/mLBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUCτ,ss After Multiple Doses of BIBF 1120 Without Pirfenidone33.7 ± 165115 ± 32.4218 ± 58.3
SecondaryCmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 without pirfenidone. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

Time frame:
pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone
ng/mLBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of BIBF 1120 Without Pirfenidone9.09 ± 17320.0 ± 64.539.7 ± 68.1
SecondaryAUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone

AUCτ,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone in the time frame mentioned. Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

Time frame:
pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Reported as:
Geometric mean · ng*h/mL
AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone
ng*h/mLBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUCτ,ss After Multiple Doses of BIBF 1120 With Pirfenidone67.9 ± 16.786.0 ± 62.7149 ± 18.0
SecondaryCmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points over a uniform dosing interval τ after multiple doses of BIBF 1120 with pirfenidone Detailed outcome measure time frame: In 50 mg and 100 mg dose group: BIBF 1120: days 14 (-1, +3) to 17 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose In 150 mg dose group: BIBF 1120: days 28 (-1, +3) to 31 at Visit 5: At pre-dose and 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose

Time frame:
pre-dose, then 0.5 h, 1 h, 2 h, 3 h, 3.92 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h after morning dose on days 14 to 17 (BIBF 1120 50 mg and 100 mg) or on days 28 to 31 (BIBF 1120 150 mg)
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone
ng/mLBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of BIBF 1120 With Pirfenidone10.9 ± 50.313.8 ± 11323.5 ± 27.2
SecondaryAUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

AUC0-4,ss was calculated as the area under the curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast) in the time frame mentioned.

Time frame:
Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Reported as:
Geometric mean · ng*h/mL
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
ng*h/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)28900 ± 30.734400 ± 36.345800 ± 26.632500 ± 21.2
SecondaryCmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after breakfast)

Time frame:
Day -1 at Visit 1: At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)
ng/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Breakfast)11300 ± 22.111900 ± 28.914600 ± 41.511200 ± 26.6
SecondaryAUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

AUC0-4,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 4 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast) in the time frame mentioned.

Time frame:
Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Reported as:
Geometric mean · ng*h/mL
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
ng*h/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUC0-4,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)28800 ± 6.8534300 ± 39.935000 ± 32.235900 ± 21.8
SecondaryCmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after breakfast)

Time frame:
Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): At pre-dose and 0.5 h, 1 h, 2 h, 3 h after morning dose and pre-dose after lunch dose
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)
ng/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Breakfast)12000 ± 23.112800 ± 44.315300 ± 51.112600 ± 27.2
SecondaryAUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg without BIBF 1120 (after lunch) in the time frame mentioned.

Time frame:
Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Reported as:
Geometric mean · ng*h/mL
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
ng*h/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)56600 ± 25.872800 ± 40.784100 ± 11.460900 ± 22.9
SecondaryCmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg Without BIBF 1120 (after lunch)

Time frame:
Day -1 at Visit 1: at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)
ng/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of Pirfenidone 600 mg Without BIBF 1120 (After Lunch)13500 ± 19.914600 ± 20.915100 ± 19.512900 ± 30.2
SecondaryAUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

AUC0-8,ss was calculated as the area under the concentration-time curve of the concentration-time profile of the analyte in plasma at steady state over the time interval from 0 to 8 hours after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch) in the time frame mentioned.

Time frame:
Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Reported as:
Geometric mean · ng*h/mL
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
ng*h/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
AUC0-8,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)47000 ± 13.671000 ± 40.871500 ± 19.163600 ± 27.7
SecondaryCmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)

Maximum measured concentration of the analyte in plasma at steady state was identified from measurements obtained at multiple time points after multiple doses of Pirfenidone 600 mg with BIBF 1120 (after lunch)

Time frame:
Day 14 at Visit 5 (BIBF 1120 50mg and 100mg) and day 28 (visit 7) (BIBF 1120 150mg): at pre-dose and 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h after lunch dose
Reported as:
Geometric mean · ng/mL
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)
ng/mLPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Cmax,ss After Multiple Doses of Pirfenidone 600 mg With BIBF 1120 (After Lunch)10700 ± 18.812000 ± 37.312100 ± 10.712500 ± 23.0
SecondaryWithdrawal Due to Adverse Event

Number of patients prematurely discontinued from trial medication due to adverse event.

Time frame:
after the first drug intake until 28 days from the last treatment administration, up to 60 days
Reported as:
Number · participants
Withdrawal Due to Adverse Event
participantsPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
With Pirfenidone (N= 5, 4, 4, 13)0002
Without Pirfenidone (N = 7, 2, 4, 11)0002
SecondaryClinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background

Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - No pirfenidone background

Time frame:
after the first drug intake until 28 days from the last treatment administration, up to 60 days
Reported as:
Number · participants
Clinical Relevant Abnormalities in Laboratory Parameters- No Pirfenidone Background
participantsPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Alanine aminotransferase increased0002
Aspartate aminotransferase increased0002
Blood creatine phosphokinase increased0001
Gamma-glutamyltransferase increased0001
SecondaryClinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background

Number of patients with Clinical Relevant Abnormalities in laboratory parameters reported as adverse events - With pirfenidone background

Time frame:
after the first drug intake until 28 days from the last treatment administration, up to 60 days
Reported as:
Number · participants
Clinical Relevant Abnormalities in Laboratory Parameters- With Pirfenidone Background
participantsPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Hypothyroidism0001
Transaminases increased0001
SecondaryChange From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Change from baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
mmHgPlaceboBIBF 1120 150 mg
DBP0.5 ± 13.3-0.8 ± 10.8
SBP1.3 ± 19.22.5 ± 14.4
SecondaryChange From Baseline in Pulse Rate

Change from baseline in pulse rate at day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · bpm
Change From Baseline in Pulse Rate
bpmPlaceboBIBF 1120 150 mg
Change From Baseline in Pulse Rate-2.5 ± 15.41.9 ± 13.6
SecondaryLung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)

Change in diffusing capacity for carbon monoxide (DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · mL/min/mmHg
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)
mL/min/mmHgPlaceboBIBF 1120 150 mg
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide (DLco)-1.131 ± 1.397-0.707 ± 2.005
SecondaryLung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)

Change in Diffusing Capacity for Carbon Monoxide percent of predicted (%DLco) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · % predicted
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)
% predictedPlaceboBIBF 1120 150 mg
Lung Function Measurement: Diffusing Capacity for Carbon Monoxide Percent of Predicted (%DLco)-4.660 ± 8.020-1.193 ± 5.948
SecondaryLung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)

Change in forced expiratory volume in 1 second (FEV1) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · Liter
Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)
LiterPlaceboBIBF 1120 150 mg
Lung Function Measurement: Forced Expiratory Volume in 1 Second (FEV1)-0.021 ± 0.1070.036 ± 0.078
SecondaryLung Function Measurement: Forced Vital Capacity (FVC)

Change in forced vital capacity (FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · Liter
Lung Function Measurement: Forced Vital Capacity (FVC)
LiterPlaceboBIBF 1120 150 mg
Lung Function Measurement: Forced Vital Capacity (FVC)-0.081 ± 0.1750.050 ± 0.086
SecondaryLung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)

Change in Forced Vital Capacity percent of predicted (%FVC) from baseline to day 35. Only the results for placebo and Nintedanib 150mg arm were reported for this endpoint as nintedanib 150mg is the target dose.

Time frame:
baseline and day 35
Reported as:
Mean · % predicted
Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)
% predictedPlaceboBIBF 1120 150 mg
Lung Function Measurement: Forced Vital Capacity Percent of Predicted (%FVC)-2.311 ± 5.1931.432 ± 2.671

Adverse events

Collected over after the first drug intake until 28 days from the last treatment administration, up to 60 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/12 (0%)4/12 (33.3%)
BIBF 1120 50 mg—0/6 (0%)0/6 (0%)
BIBF 1120 100 mg—0/8 (0%)4/8 (50%)
BIBF 1120 150 mg—1/24 (4.2%)14/24 (58.3%)
Most frequent serious events
Most frequent serious events
EventPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/120/60/81/24
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mg
NauseaGastrointestinal disorders0/120/60/85/24
VomitingGastrointestinal disorders0/120/60/85/24
DiarrhoeaGastrointestinal disorders0/120/60/84/24
StomatitisGastrointestinal disorders0/120/61/81/24
NasopharyngitisInfections and infestations0/120/61/82/24
DysphoniaRespiratory, thoracic and mediastinal disorders0/120/61/80/24
ErythemaSkin and subcutaneous tissue disorders0/120/61/80/24
Abdominal discomfortGastrointestinal disorders1/120/60/81/24
Abdominal pain upperGastrointestinal disorders1/120/60/80/24
Gastritis erosiveGastrointestinal disorders1/120/60/80/24

Baseline characteristics

Treated set: all patients who received study medication and were documented to have taken at least one dose of investigational treatment

Age, Continuous
Age, Continuous(years)PlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mgTotal
Mean64.1 ± 10.366.7 ± 2.967.5 ± 7.464.7 ± 8.565.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBIBF 1120 50 mgBIBF 1120 100 mgBIBF 1120 150 mgTotal
Female124815
Male11441635
08

Study locations

8 sites
  • 1199.31.002 Boehringer Ingelheim Investigational Site
    Bunkyo-ku,Tokyo, Japan
  • 1199.31.004 Boehringer Ingelheim Investigational Site
    Hamamatsu, Shizuoka, Japan
  • 1199.31.008 Boehringer Ingelheim Investigational Site
    Himeji, Hyogo, Japan
  • 1199.31.006 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1199.31.007 Boehringer Ingelheim Investigational Site
    Sakai, Osaka, Japan
  • 1199.31.005 Boehringer Ingelheim Investigational Site
    Seto, Aichi, Japan
  • 1199.31.001 Boehringer Ingelheim Investigational Site
    Shimotsuke,Tochigi, Japan
  • 1199.31.003 Boehringer Ingelheim Investigational Site
    Yokohama, Kanagawa, Japan
09

References and documents

Publications

  • Ogura T, Taniguchi H, Azuma A, Inoue Y, Kondoh Y, Hasegawa Y, Bando M, Abe S, Mochizuki Y, Chida K, Kluglich M, Fujimoto T, Okazaki K, Tadayasu Y, Sakamoto W, Sugiyama Y. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May;45(5):1382-92. doi: 10.1183/09031936.00198013. Epub 2014 Dec 10. PubMed 25504994 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010 and a primary completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 3 years 10 months after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2010
First posted
Jun 3, 2010
Start
May 2010
Primary completionActual
Mar 2011
Results delay requested
May 16, 2014
Results first posted
Jan 6, 2015
Last update
Jan 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01136174
First posted
Jun 3, 2010
Start date
May 2010
Primary completion
Mar 2011
Results posted
Jan 6, 2015
Last update
Jan 6, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion